Comparative Pharmacology
Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE versus XYLOCAINE VISCOUS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE versus XYLOCAINE VISCOUS.
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE vs XYLOCAINE VISCOUS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine is a local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion channels, thereby blocking the initiation and conduction of nerve impulses. It also exhibits cardiac effects as a class IB antiarrhythmic agent by modulating sodium channels in myocardial cells.
Lidocaine is an amide-type local anesthetic that blocks voltage-gated sodium channels, inhibiting nerve impulse propagation and reducing pain sensation.
1-4 mg/kg via intravenous bolus, not to exceed 300 mg; may be followed by continuous infusion of 1-4 mg/min.
Adults: 5-15 mL orally (or swish and spit) 4-6 times daily, not to exceed 4 doses in 12 hours or 30 mL in 12 hours.
None Documented
None Documented
1.5–2 hours (terminal) in healthy adults; prolonged in hepatic impairment (up to 5–7 hours), heart failure (up to 10 hours), or with continuous infusion (>24 h) due to accumulation. Context: requires monitoring in hepatic or cardiac dysfunction to avoid toxicity.
Terminal elimination half-life: 1.5-2 hours in adults; prolonged in hepatic impairment or heart failure (up to 6-8 hours). In neonates, half-life may be 3-6 hours due to immature metabolism.
Renal: ~90% as metabolites (primarily monoethylglycinexylidide [MEGX] and glycinexylidide [GX]), <10% unchanged. Fecal: <1%.
Renal excretion of metabolites: ~90%. Unchanged drug: <10%. Biliary/fecal: minor.
Category A/B
Category C
Local Anesthetic / Antiarrhythmic (Class Ib)
Local Anesthetic